Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Trial Profile

Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs CB 1158 (Primary) ; Pembrolizumab (Primary)
  • Indications Bladder cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Calithera Biosciences; Incyte Corporation
  • Most Recent Events

    • 02 Nov 2017 According to a Calithera Biosciences media release, the first patient was treated in the Phase I cohort of INCB01158 and Keytruda (pembrolizumab) combination.
    • 31 Oct 2017 Planned End Date changed from 1 May 2018 to 1 May 2019.
    • 31 Oct 2017 Planned primary completion date changed from 1 May 2018 to 1 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top